Blagden SP - Search Results

1

A Phase Ib Open-Label, Dose-Escalation Study of NUC-1031 in Combination with Carboplatin for Recurrent Ovarian Cancer.

Kazmi F, Nicum S, Roux RL, Spiers L, Gnanaranjan C, Sukumaran A, Gabra H, Ghazaly E, McCracken NW, Harrison DJ, Blagden SP. Kazmi F, et al. Among authors: blagden sp. Clin Cancer Res. 2021 Jun 1;27(11):3028-3038. doi: 10.1158/1078-0432.CCR-20-4403. Epub 2021 Mar 19. Clin Cancer Res. 2021. PMID: 33741651 Clinical Trial.

2

Phase II study to evaluate combining gemcitabine with flutamide in advanced pancreatic cancer patients.

Corrie P, Mayer A, Shaw J, D'Ath S, Blagden S, Blesing C, Price P, Warner N. Corrie P, et al. Br J Cancer. 2002 Sep 23;87(7):716-9. doi: 10.1038/sj.bjc.6600523. Br J Cancer. 2002. PMID: 12232752 Free PMC article. Clinical Trial.

3

Future directions in the management of epithelial ovarian cancer.

Blagden S, Gabra H. Blagden S, et al. Future Oncol. 2008 Jun;4(3):403-11. doi: 10.2217/14796694.4.3.403. Future Oncol. 2008. PMID: 18518765 Review.

4

Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer.

Sharma R, Graham J, Mitchell H, Brooks A, Blagden S, Gabra H. Sharma R, et al. Br J Cancer. 2009 Mar 10;100(5):707-12. doi: 10.1038/sj.bjc.6604914. Epub 2009 Feb 17. Br J Cancer. 2009. PMID: 19223898 Free PMC article.

5

Promising molecular targets in ovarian cancer.

Blagden S, Gabra H. Blagden S, et al. Curr Opin Oncol. 2009 Sep;21(5):412-9. doi: 10.1097/CCO.0b013e32832eab1f. Curr Opin Oncol. 2009. PMID: 19553815 Review.

6

Polo-like kinase Plk2 is an epigenetic determinant of chemosensitivity and clinical outcomes in ovarian cancer.

Syed N, Coley HM, Sehouli J, Koensgen D, Mustea A, Szlosarek P, McNeish I, Blagden SP, Schmid P, Lovell DP, Hatzimichael E, Crook T. Syed N, et al. Among authors: blagden sp. Cancer Res. 2011 May 1;71(9):3317-27. doi: 10.1158/0008-5472.CAN-10-2048. Epub 2011 Mar 14. Cancer Res. 2011. PMID: 21402713 Free article.

7

Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies.

Olmos D, Barker D, Sharma R, Brunetto AT, Yap TA, Taegtmeyer AB, Barriuso J, Medani H, Degenhardt YY, Allred AJ, Smith DA, Murray SC, Lampkin TA, Dar MM, Wilson R, de Bono JS, Blagden SP. Olmos D, et al. Among authors: blagden sp. Clin Cancer Res. 2011 May 15;17(10):3420-30. doi: 10.1158/1078-0432.CCR-10-2946. Epub 2011 Apr 1. Clin Cancer Res. 2011. PMID: 21459796 Clinical Trial.

8

Sustained platelet-sparing effect of weekly low dose paclitaxel allows effective, tolerable delivery of extended dose dense weekly carboplatin in platinum resistant/refractory epithelial ovarian cancer.

Sharma R, Graham J, Blagden S, Gabra H. Sharma R, et al. BMC Cancer. 2011 Jul 11;11:289. doi: 10.1186/1471-2407-11-289. BMC Cancer. 2011. PMID: 21745358 Free PMC article. Clinical Trial.

9

A study of symptoms described by ovarian cancer survivors.

Stavraka C, Ford A, Ghaem-Maghami S, Crook T, Agarwal R, Gabra H, Blagden S. Stavraka C, et al. Gynecol Oncol. 2012 Apr;125(1):59-64. doi: 10.1016/j.ygyno.2011.12.421. Epub 2011 Dec 9. Gynecol Oncol. 2012. PMID: 22155797

10

Cerebral sinus thrombosis and leptomeningeal carcinomatosis in a patient with ovarian cancer.

Li HK, Harding V, Williamson R, Blagden S, Gabra H, Agarwal R. Li HK, et al. J Clin Oncol. 2012 Jan 10;30(2):e19-20. doi: 10.1200/JCO.2011.38.1426. Epub 2011 Dec 12. J Clin Oncol. 2012. PMID: 22162572 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

90 results

Search Page